This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Climent, J. Articles by Garcia-Conde, J. Search for Related Content PubMed PubMed Citation Articles by Climent, J. Articles by Garcia-Conde, J.

Genomic Loss of 18p Predicts an Adverse Clinical Outcome in Patients with High-Risk Breast Cancer¹

Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Valencia, Spain 46010

The impact of the genomic imbalances on the clinical outcomeof 34 patients with lymph-node positive high-risk breast cancer (HRBC) was investigated using comparative genomic hybridization. All of the patients were uniformly treated with high-dose chemotherapy and autologous stem cell transplantation. The average number of chromosomal imbalances per tumor was 11 (range, 2–24), including DNA overrepresentation on chromosomes 1q (59%), 17q (38%), 8q and 16p (35% each), 20q (32%), and 19p (26%), and genomic losses involving 9p and 18q (41%), 8p, 11q, and 18p (38%), 17p (32%), 4p and Xq (29%), and 16q (26%). The most significant association among genomic changes and clinical-pathological features was the correlation of the loss of 8p with progesterone receptor positivity (P < 0.005). With a median follow-up time of 74 months, 15 patients (44%) have relapsed. In the univariate analysis, patients with gain/amplification of 17q including the HER-2/neu gene locus had a longer disease-free survival (P = 0.02), whereas those with genomic loss of 18p had a higher probability of relapse (P = 0.003). In multivariate analysis, the loss of 18p was the only parameter correlated with shorter disease-free survival (relative risk, 4.8; 95% confidence interval, 1.57–14.8; P = 0.006). In summary, our data indicate that the tumoral genomic profile may represent a valuable marker for predicting the clinical outcome in HRBC. Furthermore, the genomic loss of 18p may identify a poor prognostic subgroup of patients with HRBC.

This article has been cited by other articles:

				J. Climent, P. Dimitrow, J. Fridlyand, J. Palacios, R. Siebert, D. G. Albertson, J. W. Gray, D. Pinkel, A. Lluch, and J. A. Martinez-Climent Deletion of Chromosome 11q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer Cancer Res., January 15, 2007; 67(2): 818 - 826. [Abstract] [Full Text] [PDF]

				F. Weber, Y. Xu, L. Zhang, A. Patocs, L. Shen, P. Platzer, and C. Eng Microenvironmental Genomic Alterations and Clinicopathological Behavior in Head and Neck Squamous Cell Carcinoma JAMA, January 10, 2007; 297(2): 187 - 195. [Abstract] [Full Text] [PDF]

				H. Orita, N. Sakamoto, Y. Ajioka, T. Terai, O. Hino, N. Sato, T. Shimoda, T. Kamano, M. Tsurumaru, and H. Fujii Allelic loss analysis of early-stage flat-type colorectal tumors Ann. Onc., January 1, 2006; 17(1): 43 - 49. [Abstract] [Full Text] [PDF]

				T. D. Shellenberger, A. Mazumdar, Y. Henderson, K. Briggs, M. Wang, C. Chattopadhyay, A. Jayakumar, M. Frederick, and G. L. Clayman Headpin: A Serpin with Endogenous and Exogenous Suppression of Angiogenesis Cancer Res., December 15, 2005; 65(24): 11501 - 11509. [Abstract] [Full Text] [PDF]

				M. Nessling, K. Richter, C. Schwaenen, P. Roerig, G. Wrobel, S. Wessendorf, B. Fritz, M. Bentz, H.-P. Sinn, B. Radlwimmer, et al. Candidate Genes in Breast Cancer Revealed by Microarray-Based Comparative Genomic Hybridization of Archived Tissue Cancer Res., January 15, 2005; 65(2): 439 - 447. [Abstract] [Full Text] [PDF]

				A. Bilger, L. M. Bennett, R. A. Carabeo, T. A. Chiaverotti, C. Dvorak, K. M. Liss, S. A. Schadewald, H. C. Pitot, and N. R. Drinkwater A Potent Modifier of Liver Cancer Risk on Distal Mouse Chromosome 1: Linkage Analysis and Characterization of Congenic Lines Genetics, June 1, 2004; 167(2): 859 - 866. [Abstract] [Full Text] [PDF]

				P. J. Wild, A. Reichle, R. Andreesen, G. Rockelein, W. Dietmaier, J. Ruschoff, H. Blaszyk, F. Hofstadter, and A. Hartmann Microsatellite Instability Predicts Poor Short-Term Survival in Patients with Advanced Breast Cancer after High-Dose Chemotherapy and Autologous Stem-Cell Transplantation Clin. Cancer Res., January 15, 2004; 10(2): 556 - 564. [Abstract] [Full Text] [PDF]